xanthine oxidase

Xanthine oxidase-IN-10 (XO8 analog) is an inhibitor of xanthine oxidase (XO) used in gout research.

Xanthine oxidase-IN-15 (Compound 6c) is a selective inhibitor of Xanthine oxidase (XO) with an IC50 of 0.13 μM. It inhibits XO by forming stable interactions at the enzyme's active site. Xanthine oxidase-IN-15 is primarily utilized in research related to hyperuricemia and gout.

Xanthine oxidase-IN-17 is a potent xanthine oxidase (XOD) inhibitor with an IC50 of 298 nM and a Ki of 167 nM. By inhibiting the catalytic activity of XOD, it reduces uric acid production and subsequently decreases the formation of O₂⁻ free radicals. Xanthine oxidase-IN-17 is non-cytotoxic in AML-12 liver cells while effectively inhibiting uric acid formation. It is suitable for research on hyperuricemia and gout.

Xanthine oxidase-IN-7 (compound 1h) is a potent, orally active xanthine oxidase (XO) inhibitor with an IC50 of 0.36 μM, effectively reducing serum uric acid levels and showing potential for hyperuricemia and gout research [1].

Xanthine oxidase-IN-4 (compound 19a) is an orally active and potent xanthine oxidase (XO) inhibitor with an IC50 of 0.039 μM, suitable for research in hyperuricemia and gout. Xanthine oxidase-IN-4 demonstrates hypouricemic potency in potassium oxonate-induced hyperuricemia rats. [1].

Xanthine oxidase-IN-5, a powerful and orally active inhibitor of xanthine oxidase (XO), exhibits an IC50 value of 0.70 μM. It possesses favorable drug-like characteristics, with ligand efficiency (LE) and lipophilic ligand efficiency (LLE) values of 0.33 and 3.41, respectively. Moreover, Xanthine oxidase-IN-5 showcases significant hypouricemic effects in a hyperuricemic rat model [1].

Xanthine oxidase-IN-6, a potent and orally active mixed-type inhibitor of xanthine oxidase (XOD), demonstrates significant anti-hyperuricemia and renal protective activity with an IC50 value of 1.37 µM.

Xanthine oxidase-IN-8 (Icarisids J) (Compound 7) acts as an inhibitor of xanthine oxidase with an inhibitory concentration (IC50) of 29.71 μM [1].

Xanthine Oxidase-IN-9 (also known as Icarisids E or Compound 2) effectively inhibits xanthine oxidase (XOD) with an IC50 value of 31.81 μM [1].

Xanthine Oxidase-IN-11, an analog of XO8, is an inhibitor of xanthine oxidase (XO) [1].

Xanthine oxidase-IN-12 (Compound 11), an inhibitor of xanthine oxidase (XO), has an IC50 value of 91 nM and exhibits antioxidant properties, also reducing intracellular reactive oxygen species (ROS) [1].

Xanthine oxidase (XO) is an enzyme involved in purine catabolism and conversion to uric acid, generating reactive oxygen species, used in the study of cardiovascular diseases.

Xanthine oxidase-IN-1 is an effective inhibitor of xanthine oxidase with an IC50 value of 6.5 nM. It plays a central role in purine catabolism through the degradation of bioactive nucleotides facilitated by nucleic acid and nucleotide intermediates.

Xanthine oxidase-IN-16 is an effective orally active inhibitor of xanthine oxidase (XO), demonstrating significant therapeutic efficacy in rats with hyperuricemia and an IC50 of 102 nM.

Xanthine oxidase-IN-13 (Compound 10) is a selective inhibitor of xanthine oxidase, with an IC50 of 149.56 μM for bovine xanthine oxidase. It is utilized in the study of inflammatory arthritis.

Tigulixostat (LC350189) is a novel xanthine oxidase inhibitor (XOI) that reduces uric acid production and may be used in studies of gout-related diseases.

Luvadaxistat (TAK-831) is an orally active, potent and highly selective inhibitor of D-amino acid oxidase (DAAO) with an IC50 value of 14 nM for the oxidative deamination of D-serine.Luvadaxistat is used in the study of schizophrenia and cognitive disorders.

Allopurinol (Zyloric) is a Xanthine Oxidase Inhibitor. The mechanism of action of allopurinol is as a Xanthine Oxidase Inhibitor.

Febuxostat (TEI 6720) is a xanthine oxidase inhibitor.

Benzbromarone (Desuric) is a CYP2C9 inhibitor with Ki value of 19.3 nM.

Phytic acid dodecasodium salt hydrate (myo-Inositol, hexakis(dihydrogen phosphate) dodecasodium salt hydrate) is a phosphorus storage compound of seeds and cereal grains. Phytic acid dodecasodium salt hydrate inhibits the enzymatic superoxide source xanthine oxidase with an IC50 of 6 mM and has antioxidative, neuroprotective, and anti-inflammatory effects.

Oxypurinol is a xanthine oxidase inhibitor. Oxipurinol is potentially used for the treatment of congestive heart failure.

Baicalein (5,6,7-Trihydroxyflavone) is a xanthine oxidase inhibitor.

Phytic acid (Fytic Acid) is a complexing agent for removal of traces of heavy metal ions. It acts also as a hypocalcemic agent.